Mortenson Mark 4

4 · Clene Inc. · Filed Jun 10, 2024

Form 4

Period: 2024-06-07

Chief Science Officer

Transactions

Award
Stock Options (Right to buy)
2024-06-07+800,000→ 800,000 total
Exercise: $0.37Exp: 2034-06-06→ Common Stock (800,000 underlying)
Award
Stock Options (Right to buy)
2024-06-07+2,000,000→ 2,000,000 total
Exercise: $0.37Exp: 2034-06-06→ Common Stock (2,000,000 underlying)

Footnotes (2)

[F1]This option was granted on June 7, 2024 as an option for 2,000,000 shares of Common Stock under the Clene Inc. Amended 2020 Stock Plan at an exercise price of $0.37 per share. The options vest with respect to the first 33.3% of such shares if Clene Inc. has an NDA accepted by the FDA, an additional 33.3% of such shares if Clene Inc. has an NDA approved by the FDA, and the remaining 33.4% of such shares if Clene Inc. achieves $100,000,000 in revenues in connection with the sales of any approved drugs.
[F2]This option was granted on June 7, 2024 as an option for 800,000 shares of Common Stock under the Clene Inc. Amended 2020 Stock Plan at an exercise price of $0.37 per share. The options vest with respect to the first 25% of such shares on June 7, 2025 and then in 36 equal installments of Common Stock on the 7th day of each calendar month, beginning July 7, 2025, until such shares are fully vested

Documents

1 file